The neuropathologist at Mount Sinai and chief science officer of Precise Dx pairing shared background information on the artificial intelligence’s ability to improve the diagnosis of Parkinson disease from peripheral tissue biopsies. [WATCH TIME: 9 minutes]
The findings in Alzheimer disease further elucidated the safety profile of AMX0035, as treatment emergent adverse events in the PEGASUS trial appeared to be largely disease driven.
The president of the National Headache Foundation discussed whether switching or continuing preventive medications has a benefit in patients who have chronic migraine with medication overuse. [WATCH TIME: 4 minutes]
The Parkinson’s Foundation will now partner with Morehouse School of Medicine, aiming to make the study and genetic testing more accessible for Black and African American persons in Atlanta.
Cerebrospinal fluid samples tested in a large cohort of patients at least 50 years of age with either mild cognitive impairment or Alzheimer disease showed high correlations between the Lumipulse G ß-Amyloid Ratio and PET status.
Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.
The neurologist at Christus St. Vincent Health System detailed the areas of research dedicated to understanding more about neuropsychiatric symptoms of Parkinson disease and the root causes of the disease. [WATCH TIME: 3 minutes]
Vincent Martin, MD, president of the National Headache Foundation, provided insight on the ongoing challenges of treatment optimization for patients with chronic migraine.
Over the 36-month period of the FIREFISH study and its extension, treatment with risdiplam (Evrysdi; Genentech) resulted in decreased rate of adverse events, serious adverse events, and number of hospitalizations.
The phase 2 study will feature a 24-week treatment period followed by an 80-week open-label treatment period with the small-molecule RIPK1 inhibitor. It seeks to enroll 260 patients with ALS.
Using this new methodology, 78% of patients with progressive multiple sclerosis demonstrated large treatment benefits with the siponimod (Mayzent; Novartis) on at least 1 of 4 clinical outcomes.
The effects of amyloid-ß and white matter hyperintensity volume on rates of neurodegeneration remained similar in cognitively normal individuals when they were assessed together as predictors in the same model.
A greater number of hypothalamic wake-promoting neurons were associated with a lower percentage of time in stage 2 of non-REM sleep and REM stages.
Axsome expects to address the concerns in the letter and plans to resubmit AXS-07. The MoSEIC meloxicam-rizatriptan combination significantly reduced migraine symptoms and pain compared with placebo and both active agents in a pair of phase 3 trials.
The professor of neurology at the University of Basel provided insight on a new methodology that allows depiction of patient profiles from baseline characteristics and their associations with individual outcomes. [WATCH NOW: 5 minutes]
Here's what is coming soon to NeurologyLive®.
The neurologist at Christus St. Vincent Health System provided insight on the desperate need for new medications for both motor and nonmotor symptoms of Parkinson disease. [WATCH TIME: 3 minutes]
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is stroke.
Vincent Martin, MD, president of the National Headache Foundation, discussed the MOTS trial, a non-inferiority study aimed at understanding treatment strategies with preventives for chronic migraine.
Baseline neurofilament light levels were associated with future disability progression and degree of brain atrophy regardless of the presence or absence of acute disease activity.
Neurology News Network for the week ending April 30, 2022. [WATCH TIME: 4 minutes]
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 29, 2022.
Shurjal Baxi, MD, MPH, the senior vice president of Clinical and Scientific Solutions at Verana Health, shared her perspective on the AAN’s Axon Registry and how quality data collection can drive improvements in patient care and management.
Peter J. McAllister, MD, FAAN, medical director and chief medical officer, New England Center for Neurology and Headache, offered his insight into data from the phase 2 STEMTRA trial in TBI and the trends he’s observed in the field of regenerative medicine.
A best-case analysis indicated that, for amyloid-positive patients diagnosed with MCI due to AD or mild AD dementia, lecanemab plus standard of care provided an additional gain of 0.75 in quality-adjusted life years.
Pitolisant, an agent that originally received FDA-approval in 2019 to treat excessive daytime sleepiness in narcolepsy, will have efficacy and safety evaluated in a cohort of 200 patients with idiopathic hypersomnia.
The approval is supported by phase 3 data which showed statistically significant differences on MG-ADL and QMG scores relative to placebo following 26 weeks of treatment.
The assistant professor of neurology and director of the Parkinson’s Disease & Movement Disorder Program at Global Neurosciences Institute provided insight on the areas of focus during Parkinson Awareness Month. [WATCH TIME: 3 minutes]
Expert clinicians offer their insight on the associations between stroke and COVID-19, treatment for traumatic brain injury, the latest on aducanumab, priorities for research in migraine, and more, from the 2022 American Academy of Neurology Annual Meeting.
The difference in inflammatory disease activity between men and women faded after the age of 50 years, whereas the sex difference in the neurodegenerative component of MS became apparent after the age of 45 years and deepened with older age.
